Corcept Therapeutics (CORT) Equity Ratio (2010 - 2026)

Corcept Therapeutics has disclosed Equity Ratio across 17 years of filings, most recently posting 0.78 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.78, down 3.01% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.78 (down 3.01% YoY), and the FY2025 annual result was 0.77, down 4.23% from the prior year.
• Equity Ratio came in at 0.78 for Q1 2026 at Corcept Therapeutics, up from 0.77 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.89 in Q2 2022 to a low of 0.77 in Q3 2025.
• The 5-year median for Equity Ratio is 0.81 (2024), against an average of 0.82.
• Across the five-year window, Equity Ratio fell 12.45% in 2023 and climbed 4.81% in 2024, its largest moves.
• Corcept Therapeutics' Equity Ratio stood at 0.86 in 2022, then dropped by 5.22% to 0.82 in 2023, then retreated by 0.83% to 0.81 in 2024, then decreased by 4.23% to 0.77 in 2025, then gained by 1.12% to 0.78 in 2026.
• The last three Equity Ratio figures came in at 0.78 (Q1 2026), 0.77 (Q4 2025), and 0.77 (Q3 2025), per Business Quant data.